Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Onivyde Too Expensive For NICE, Despite Dearth Of Pancreatic Cancer Drugs

Executive Summary

NICE has not recommended Shire's Onivyde in draft guidance as it is not cost effective, the HTA body for England and Wales said. The pancreatic cancer treatment has also struggled to make its mark on the US market where it is being commercialized by Merrimack Pharmaceuticals.


Related Content

Ipsen Pays $575m Upfront For Struggling Pancreatic Drug Onivyde
Merrimack's Slow Ramp-up For Onivyde Prompts Cutbacks


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts